Business
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, has named Dr. Jeff Miller, renowned NK Cell Cancer Specialist as Consulting Chief Medical Officer. Dr. Miller* is currently Professor of Medicine at the University of Minnesota** and is the Deputy Director of the University of Minnesota’s Masonic Comprehensive Cancer Center. Dr. Miller has more than 25 years of experience studying the biology of NK cells, and other immune effector cells and their use in clinical immunotherapy with over 300 peer-reviewed publications. Dr. Miller is a board certified physician specializing in hematological oncology. Dr. Miller is a member of numerous medical societies such as the American Society of Hematology, the American Association of Immunologists, and has been a member of the American Society of Clinical Investigation since 1999. Dr. Miller serves on the editorial board for Transplantation and Cell Therapy and is a reviewer for a number of journals and NIH grants. Dr. Miller’s current discovery and research themes in the Miller Laboratory include: NK cells and their receptors after hematopoietic cell transplantationCMV induced adaptive NK cells exhibit enhanced function through CD16Induction of NK cells antigen specificity through CD16 targetingPreserving and enhancing NK cell function through antibody dependent cellular cytotoxicity (ADCC) Simultaneous to Dr. Miller’s appointment GT Biopharma announces the departure of Dr. Greg Berk as President of Research & Development and Chief Medical Officer. Michael Breen, Executive Chairman and Interim CEO of GT Biopharma commented on the occasion, “On behalf of the Company and the Board of Directors, we would like to welcome Dr. Jeff Miller once again to the role of consulting Chief Medical Officer. We are grateful for his continued efforts in advancing GT Biopharma’s platform of proprietary NK Cell engager (TriKE®) technology. Additionally, we wish Dr. Berk well in his future endeavors.” About GT Biopharma, Inc.GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products ba...